NYSE · BSX
Boston Scientific Corporation
$42.69+$0.26 (+0.61%)
Boston Scientific Corporation’s quoted price sits in the lower half of its reported 52-week range, 59.59% below the high.
Loading market information…
NASDAQ · MMSI · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Merit Medical Systems, Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.66% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Merit Medical Systems, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Merit Medical Systems, Inc. (MMSI) is engaged in the design, development, manufacturing, and worldwide commercialization of disposable medical products. These devices are crucial for a broad spectrum of diagnostic, therapeutic, and interventional procedures, primarily within the fields of cardiology, radiology, oncology, critical care, and endoscopy. The company operates through two main divisions: Cardiovascular and Endoscopy. Its extensive product portfolio includes advanced solutions for diagnosing and treating conditions in peripheral vessels and organs, as well as a comprehensive suite of cardiac intervention products. The latter encompasses tools for vascular access, angiography, electrophysiology, cardiac rhythm management, fluid and hemodynamic monitoring, hemostasis, and various interventional therapies for heart-related ailments. Additionally, MMSI provides customized procedural solutions, offering critical care items, disinfection protection systems, specialized syringes, manifold kits, and tailored trays and packs. Their offerings further extend to coated tubes and wires, alongside sophisticated sensor components for microelectromechanical systems (MEMS). The company also features pulmonary products, such as laser-cut tracheobronchial stents with their accompanying over-the-wire and direct visualization delivery systems, and dilation balloons used for endoscopic stricture dilation. Gastroenterology products, as well as essential kits and accessories for endoscopy and bronchoscopy procedures, complete their diverse catalog. Merit Medical Systems sells its products to a wide client base, including hospitals and healthcare professionals (physicians, technicians, and nurses) working in alternative care settings. Distribution channels include a direct sales force, authorized distributors, original equipment manufacturer (OEM) partnerships, and custom procedure tray manufacturers, reaching customers throughout the United States and internationally. Founded in 1987, Merit Medical Systems, Inc. has its corporate headquarters situated in South Jordan, Utah.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:16 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $382.46M+2.96% vs estimate |
| Q1 2025 | Apr 24, 2025 | $0.86+14.82% vs estimate | $355.35M+0.8% vs estimate |
|---|
| Q4 2024 | Feb 25, 2025 | $0.93+13.41% vs estimate | $355.16M+1.03% vs estimate |
|---|
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
15 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 6 contributors · Median target $100.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$42.69+$0.26 (+0.61%)
Boston Scientific Corporation’s quoted price sits in the lower half of its reported 52-week range, 59.59% below the high.
$198.34+$3.18 (+1.63%)
Becton, Dickinson and Company’s quoted price sits in the upper half of its reported 52-week range, 1.06% below the high.
$83.56+$1.71 (+2.09%)
Solventum Corporation’s quoted price sits in the upper half of its reported 52-week range, 11.26% below the high.
$141.39+$2.41 (+1.73%)
Teleflex Incorporated’s quoted price sits in the upper half of its reported 52-week range, 2.49% below the high.
$168.65+$2.26 (+1.36%)
ICU Medical, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.55% below the high.
$62.48+$1.06 (+1.73%)
AtriCure, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.83% below the high.
$85.27+$2.40 (+2.9%)
LeMaitre Vascular, Inc.’s quoted price sits in the lower half of its reported 52-week range, 27.74% below the high.
$45.72-$0.04 (-0.09%)
CONMED Corporation’s quoted price sits in the upper half of its reported 52-week range, 14.8% below the high.
